3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
3
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Pancreatic Neoplasms
14
Colorectal Neoplasms
13
Rectal Neoplasms
5
Colonic Neoplasms
4
Adenocarcinoma
4
Liver Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Neoplasm Metastasis
2
Melanoma
2
Esophageal Neoplasms
2
Barrett Esophagus
2
Adenocarcinoma Of Esophagus
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Resectable Pancreatic Ductal Adenocarcinoma
1
Prostatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Ovarian Neoplasms
1
Obesity
1
Non-DM Stage II High-risk Colorectal Cancer
1
Neoplasms
1
Motor Activity
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Insulin Resistance
1
Hepatitis C, Chronic
1
Glioma
1
Interventions
pembrolizumab
39
Nivolumab
15
Gemcitabine
8
spartalizumab
7
atezolizumab
7
Carboplatin
7
Cyclophosphamide
6
130-nm albumin-bound paclitaxel
6
durvalumab
5
Cisplatin
5
Bevacizumab
5
fludarabine
4
budigalimab
4
Paclitaxel
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorouracil
4
Cetuximab
4
Albumin-Bound Paclitaxel
4
tislelizumab
3
lenvatinib
3
cemiplimab
3
avelumab
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
HMPL-013
3
Fulvestrant
3
Docetaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Metformin
×
Gastrointestinal
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn